About 1.7 million women will have a breast biopsy each year. It’s an invasive, painful, and costly test that comes back negative about 60 percent of the time. Now, there’s a new way to tell whether a mass is cancerous, and there’s no needle required!
Playing hide and go seek, or playing the piano, when 3-year-old Kadin is around, Grandma Roz is always playing something.
“I am blessed by all my grandchildren, but this one’s got me,” Roz Sobel told Ivanhoe.
She’s needed the distraction. A few months ago, doctors found a lump on Roz’s mammogram. It was a scary moment for a woman whose mother, grandmother, sister, cousin, and niece all had breast cancer.
“My family has a horrible history,” Roz said.
Typically—women like Roz will need a painful needle biopsy to determine if the lump is cancerous, but she took part in a clinical trial testing a new technology called opto-acoustics.
“The thought is that this will help us determine what’s cancer and what’s not,” Paulette Lebda, MD, Breast Radiologist, The Cleveland Clinic, told Ivanhoe.
An ultrasound with a laser is used to look at the distribution of oxygenated and deoxygenated blood in the lump. It’s essentially a blood map for doctors.
“Usually, benign breast masses can have a different blood profile, or blood map, than cancerous masses,” Dr. Lebda said.
Studies have shown the technique could reduce the number of biopsies by 40-percent, which was music to Roz’s ears.
It turned out her lump was caused by a dog jumping on her, not cancer.
“They knew right then and there that it was from the dog,” Roz explained.
With the opto-acoustics technology, there’s no radiation, no needle, no pain, and no risk to the patient. The technique is being studied in a clinical trial at 16 centers around the country. It will not replace mammograms, but may decrease the need for invasive biopsies by distinguishing cancerous from noncancerous breast masses through imaging.
BACKGROUND: Imaging techniques, like a MRI or a mammogram, along with physical exams of the breast can lead doctors to suspect that a person has breast cancer. However, the only way to know for sure is to take a sample of tissue from the suspicious area, called a biopsy. Usually, if the doctor notices anything suspicious he or she will order a biopsy. The tissue sample is examined by a pathologist to see if cancer cells are present or not. (Source: http://www.breastcancer.org/symptoms/testing/types/biopsy)
HOW IT IS DONE: There are several ways to do a breast biopsy, including:
* Fine-needle aspiration biopsy: the doctor inserts a thin needle into a lump and removes a sample of cells or fluid.
* Core needle biopsy: the doctor inserts a needle with a special tip and removes a sample of breast tissue about the size of a grain of rice.
* Open (surgical) biopsy: the doctor will make a small cut in the skin and breast tissue to remove part or all of a lump. This may be done as a first step to check a lump or if a needle biopsy does not provide enough information.
* Vacuum-assisted core biopsy: this is performed with a probe that uses a gentle vacuum to remove the breast tissue sample. The small cut does not require stitches and leaves a very small scar. (Source: www.webmd.com)
OPTOACOUSTIC TECHNIQUE: The Cleveland Clinic, along with 15 other sites across the country, are testing a new technique that could cut down on the number of invasive breast biopsies. Almost two million women in the U.S. undergo a needle or surgical biopsy every year, and about 60 percent of the masses are non-cancerous. The trial (PIONEER-01 trial) is designed to gauge the effectiveness of Imagio (an imaging device), which combines ultrasound with opto-acoustics, an imaging technology based on sound and light. Imagio doesn’t require radiation from X-ray, or contrast agents injected into a person’s bloodstream, to get the high-resolution images that researchers say can distinguish if a breast mass is cancerous. The device is a handheld probe that moves along the surface of the skin to pick up signals. The process takes about 15 minutes. The opto-acoustic technique shows the presence of blood vessel networks. The vessels that grow around cancerous tissue are filled with oxygen or have very little oxygen in them. If the suspicious tissue mass doesn’t have any of those characteristics, then the mass is more likely to be non-cancerous. If the device gets FDA approval based on results of the PIONEER-01 trial, then researchers believe it will be at least a couple of years before Imagio is available for clinical use. For more information on enrolling, go to: http://clinicaltrials.gov/ct2/show/NCT01943916. (Source: The Cleveland Clinic and http://www.cleveland.com/healthfit/index.ssf/2014/02/cleveland_clinic_part_of_study.html)
? For More Information, Contact:
Media Relations Manager
The Cleveland Clinic
A recall for epipen devices has expanded in the US and…
Dentistry from the Heart gets underway at 7:30 Friday morning.
Banner Health in Phoenix is starting the first phase of a clinical…